Literature DB >> 11870871

Expression of fractalkine (CX3CL1) and its receptor, CX3CR1, during acute and chronic inflammation in the rodent CNS.

Paula Marie Hughes1, Michelle Sandra Botham, Stefan Frentzel, Anis Mir, Victor Hugh Perry.   

Abstract

In this study, we investigate the expression of fractalkine (CX3CL1) and the fractalkine receptor (CX3CR1) in the naive rat and mouse central nervous system (CNS). We determine if the expression of this chemokine and its receptor are altered during chronic or acute inflammation in the CNS. In addition, we determine if CX3CL1, which has been reported to be chemoattractant to leukocytes in vitro, is capable of acting as a chemoattractant in the CNS in vivo. Immunohistochemistry was performed using primary antibodies recognizing soluble and membrane-bound CX3CL1 and the N-terminus of the CX3CR1. We found that neurons in the naive rodent brain are immunoreactive for CX3CL1 and CX3CR1, both showing a perinuclear staining pattern. Resident microglia associated with the parenchyma and macrophages in the meninges and choroid plexus constituitively express CX3CR1. In a prion model of chronic neurodegeneration and inflammation, CX3CL1 immunoreactivity is upregulated in astrocytes and CX3CR1 expression is elevated on microglia. In surviving neurons, expression of CX3CL1 appears unaltered relative to normal neurons. There is a decrease in neuronal CX3CR1 expression. Acute inflammatory responses in the CNS, induced by stereotaxic injections of lipopolysaccharide or kainic acid, results in activation of microglia and astrocytes but no detectable changes in the glial expression of CX3CL1 or CX3CR1. The expression of CX3CL1 and CX3CR1 by glial cells during inflammation in the CNS may be influenced by the surrounding cytokine milieu, which has been shown to differ in acute and chronic neuroinflammation. Copyright 2002 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11870871

Source DB:  PubMed          Journal:  Glia        ISSN: 0894-1491            Impact factor:   7.452


  88 in total

Review 1.  Chemokines and glial cells: a complex network in the central nervous system.

Authors:  Elena Ambrosini; Francesca Aloisi
Journal:  Neurochem Res       Date:  2004-05       Impact factor: 3.996

2.  In vivo structure/function and expression analysis of the CX3C chemokine fractalkine.

Authors:  Ki-Wook Kim; Alexandra Vallon-Eberhard; Ehud Zigmond; Julia Farache; Elias Shezen; Guy Shakhar; Andreas Ludwig; Sergio A Lira; Steffen Jung
Journal:  Blood       Date:  2011-09-27       Impact factor: 22.113

3.  Photobiomodulation-induced analgesia in experimental temporomandibular disorder involves central inhibition of fractalkine.

Authors:  João Ignácio Ferrara-Jr; Everton Tiago de Souza; Adriano Cardozo Franciosi; Elaine Flamia Toniolo; Camila Squarzoni Dale
Journal:  Lasers Med Sci       Date:  2019-04-10       Impact factor: 3.161

Review 4.  CNS immune privilege: hiding in plain sight.

Authors:  Monica J Carson; Jonathan M Doose; Benoit Melchior; Christoph D Schmid; Corinne C Ploix
Journal:  Immunol Rev       Date:  2006-10       Impact factor: 12.988

Review 5.  Microglia in prion diseases.

Authors:  Adriano Aguzzi; Caihong Zhu
Journal:  J Clin Invest       Date:  2017-07-17       Impact factor: 14.808

Review 6.  Exploring the neuroimmunopharmacology of opioids: an integrative review of mechanisms of central immune signaling and their implications for opioid analgesia.

Authors:  Mark R Hutchinson; Yehuda Shavit; Peter M Grace; Kenner C Rice; Steven F Maier; Linda R Watkins
Journal:  Pharmacol Rev       Date:  2011-07-13       Impact factor: 25.468

7.  Interactions between chemokine and mu-opioid receptors: anatomical findings and electrophysiological studies in the rat periaqueductal grey.

Authors:  Silke Heinisch; Jonathan Palma; Lynn G Kirby
Journal:  Brain Behav Immun       Date:  2010-10-23       Impact factor: 7.217

8.  Retinal vascular repair and neovascularization are not dependent on CX3CR1 signaling in a model of ischemic retinopathy.

Authors:  Lian Zhao; Wenxin Ma; Robert N Fariss; Wai T Wong
Journal:  Exp Eye Res       Date:  2009-01-07       Impact factor: 3.467

9.  Expression of fractalkine and fractalkine receptor in urinary bladder after cyclophosphamide (CYP)-induced cystitis.

Authors:  Ruhin Yuridullah; Kimberly A Corrow; Susan E Malley; Margaret A Vizzard
Journal:  Auton Neurosci       Date:  2006-05-02       Impact factor: 3.145

10.  Next-generation active immunization approach for synucleinopathies: implications for Parkinson's disease clinical trials.

Authors:  Markus Mandler; Elvira Valera; Edward Rockenstein; Harald Weninger; Christina Patrick; Anthony Adame; Radmila Santic; Stefanie Meindl; Benjamin Vigl; Oskar Smrzka; Achim Schneeberger; Frank Mattner; Eliezer Masliah
Journal:  Acta Neuropathol       Date:  2014-02-14       Impact factor: 17.088

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.